Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Artra Group Corporation (6029.T)
Osaka, JP
Artra Group Corporation delivers diverse support services to acupuncture and osteopathic clinics across Japan. Its offerings encompass billing solutions and HONEY-STYLE, a specialized platform facilitating word-of-mouth marketing and reservation management for acupuncture and moxibustion practices. The company also operates the Atlas Store, an e-commerce site providing essential consumables for these facilities. Additionally, it runs a portal site, accessible via its website and e-mail magazine, which distributes information to judo reduction instructors, acupuncturists/moxibustion practitioners, and anma massage shiatsu therapists. Nursing care services are also part of its portfolio. Formerly known as artra corporation, the company adopted its present name, Artra Group Corporation, in 2021. Founded in 2005, its headquarters are situated in Osaka, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.54% | +2.75% | +7.47% | +19.87% | +16.88% | +6.86% | +0.54% | +2.75% | -42.28% | -85.06% | -44.62% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%-7.3% Q1'26: -1.0% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+800.8% ★ Q1'26: -477.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+6.3% ★ Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+3.6% Q1'26: +1.8% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+8.7% ★ Q1'26: +6.3% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+0.3% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×4.27× ★ Q1'26: 5.03× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
|---|---|---|---|---|---|---|---|
| Revenue |
2.56B
est: 2.02B (+26.9%)
|
3.25B
est: 3.45B (-5.8%)
|
3.76B
est: 3.80B (-1.1%)
|
3.48B
est: 3.67B (-5.2%)
|
2.83B
est: 3.20B (-11.4%)
|
2.43B
est: 4.07B (-40.4%)
|
3.16B
est: 5.28B (-40.2%)
|
| EBITDA |
502.85M
est: -7.68M (+6,650.8%)
|
322.30M
est: -13.11M (+2,558.4%)
|
555.60M
est: -14.44M (+3,947.6%)
|
727.88M
est: -13.95M (+5,319.2%)
|
77.49M
est: -12.16M (+737.2%)
|
-226.70M
est: -15.47M (-1,365.8%)
|
-163.55M
est: -20.06M (-715.1%)
|
| EBIT |
456.57M
est: -97.22M (+569.6%)
|
251.98M
est: -166.04M (+251.8%)
|
450.19M
est: -182.88M (+346.2%)
|
608.71M
est: -176.63M (+444.6%)
|
-58.14M
est: -154.01M (+62.3%)
|
-403.86M
est: -195.88M (-106.2%)
|
-320.31M
est: -254.11M (-26.0%)
|
| Net Income |
268.73M
est: 209.77M (+28.1%)
|
148.70M
est: 377.59M (-60.6%)
|
301.43M
est: 234.33M (+28.6%)
|
269.93M
est: 654.90M (-58.8%)
|
-146.66M
est: 52.19M (-381.0%)
|
-440.76M
est: 127.91M (-444.6%)
|
-351.12M
est: 502.43M (-169.9%)
|
| SGA |
625.38M
est: 658.87M (-5.1%)
|
923.48M
est: 1.13B (-17.9%)
|
893.45M
est: 1.24B (-27.9%)
|
955.82M
est: 1.20B (-20.2%)
|
885.51M
est: 1.04B (-15.2%)
|
858.20M
est: 1.33B (-35.4%)
|
1.06B
est: 1.72B (-38.5%)
|
| EPS |
34.45
est: 20.50 (+68.0%)
|
18.41
est: 36.90 (-50.1%)
|
34.59
est: 22.90 (+51.0%)
|
30.88
est: 64.00 (-51.8%)
|
-16.71
est: 5.10 (-427.6%)
|
-49.87
est: 12.50 (-499.0%)
|
-36.76
est: 49.10 (-174.9%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-14 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-01 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hiroyuki Kyuse | Chief Executive Officer, President, Head of Acupuncture & Orthopedic Clinic Support Dept. and Chairman | — | male |
| Katsunori Tanaka | Director of Accounting & Finance, In Charge of General Affairs & HR Department and Director | — | male |
| Toru Katada | GM of Development Planning Department & Information Systems Department and Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6029.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
